Shuhei Okada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuhei Okada has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Kazuyuki Numakura
Department of Urology Akita University Graduate School of Medicine Akita Japan
2 shared publicationsMitsuru Saito
Department of Urology Akita University Graduate School of Medicine Akita Japan
2 shared publicationsRyohei Yamamoto
Department of Urology Akita University Graduate School of Medicine Akita Japan
2 shared publications- Shintaro Narita
Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
2 shared publications Tomonori Habuchi
Department of Urology Akita University Graduate School of Medicine Akita Japan
2 shared publicationsYasushi Ichimura
Department of Urology Mito Medical Center Higashiibaraki‐gun Japan
2 shared publications
Latest Publications
- 12 November 2026
- Published by Oxford University Press (OUP) in Carcinogenesis
Lard-Based Diet Promotes Prostate Cancer Progression through Gut microbiota-Driven Immune Suppression in the Tumor Microenvironment
Growing epidemiological evidence indicates that dietary fats and obesity are linked to prostate cancer (PCa) progression. This study examines the impact of a lard-based diet (LD) on PCa progression through gut microbiota alterations and immune modulation. Using a prostate-specific Pten knockout mouse model, LD increased the relative abundance of the phylum Proteobacteria, which correlated with higher serum lipopolysaccharide (LPS) levels, weight gain, activation of TGF-β signaling, and accelerated PCa growth. Moreover, LD promoted Foxp3+ T cell infiltration within tumors, enhancing the immunosuppressive tumor microenvironment and driving cancer progression. Antibiotic treatment reduced both Foxp3+ T cell infiltration and serum LPS levels, highlighting the role of gut microbiota in PCa progression. Moreover, inhibiting LPS signaling suppressed high-fat diet-induced Foxp3+ T cell infiltration. In clinical samples, obesity was associated with increased FOXP3+ T cell infiltration in the prostate, while an abundance of gut class ε-Proteobacteria correlated with obesogenic phenotypes and advanced PCa features. These findings suggest that LD-induced gut microbiota changes and immune modulation contribute to PCa progression via systemic inflammation and intratumoral TGF-β signaling, presenting a potential preventive and therapeutic target for PCa.
- 12 November 2026
- Published by Oxford University Press (OUP) in Carcinogenesis
Lard-Based Diet Promotes Prostate Cancer Progression through Gut microbiota-Driven Immune Suppression in the Tumor Microenvironment
Growing epidemiological evidence indicates that dietary fats and obesity are linked to prostate cancer (PCa) progression. This study examines the impact of a lard-based diet (LD) on PCa progression through gut microbiota alterations and immune modulation. Using a prostate-specific Pten knockout mouse model, LD increased the relative abundance of the phylum Proteobacteria, which correlated with higher serum lipopolysaccharide (LPS) levels, weight gain, activation of TGF-β signaling, and accelerated PCa growth. Moreover, LD promoted Foxp3+ T cell infiltration within tumors, enhancing the immunosuppressive tumor microenvironment and driving cancer progression. Antibiotic treatment reduced both Foxp3+ T cell infiltration and serum LPS levels, highlighting the role of gut microbiota in PCa progression. Moreover, inhibiting LPS signaling suppressed high-fat diet-induced Foxp3+ T cell infiltration. In clinical samples, obesity was associated with increased FOXP3+ T cell infiltration in the prostate, while an abundance of gut class ε-Proteobacteria correlated with obesogenic phenotypes and advanced PCa features. These findings suggest that LD-induced gut microbiota changes and immune modulation contribute to PCa progression via systemic inflammation and intratumoral TGF-β signaling, presenting a potential preventive and therapeutic target for PCa.
- 6 November 2025
- Published by Wiley in The Prostate
- Vol. 86 (3) , 357-364
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone‐Sensitive Prostate Cancer
Background: This study evaluates the impact of early modification of upfront androgen receptor signaling inhibitors (ARSI) on outcomes among patients with metastatic hormone‐sensitive prostate cancer (mHSPC). Methods: This retrospective, multicenter cohort study included 590 patients with mHSPC who received upfront ARSI combined with androgen deprivation therapy. All had a follow‐up duration of ≥ 6 months. The impact of early modification of ARSI without progression on survival outcomes was analyzed. The inverse probability of treatment weighting (IPTW) was applied to adjust for confounding factors associated with survival outcomes, comparing patients who did and did not discontinue ARSI early. Results: Upfront abiraterone acetate, apalutamide, and enzalutamide were used in 50.8%, 28.1%, and 21.0% of patients, respectively. The rates of withdrawal of the upfront ARSI and initial dose reduction were 21.2% and 6.1%, respectively. The highest withdrawal rate (33.1%) was with apalutamide, mainly due to adverse events (89.1%). Apalutamide use (odds ratio [OR] 2.39, 95% CI: 1.50–3.80) and a low‐risk CHAARTED status (OR 1.84, 95% CI: 1.08–3.14) were identified as independent risk factors for early ARSI withdrawal. IPTW analysis revealed early ARSI withdrawal (within 6 months) significantly correlated with poor castration‐resistant prostate cancer‐free survival (CRPC‐FS) ( p = 0.004) and second progression‐free survival (PFS2) ( p = 0.035). However, it had no significant relationship with overall survival ( p = 0.280). Conclusions: Early withdrawal of initial upfront ARSI was associated with poor CRPC‐FS and PFS2 among mHSPC patients. Maximizing the effectiveness of first‐line treatment requires optimal management of ARSI therapy. Trial Registration: jRCTs021180021.
- 6 November 2025
- Published by Wiley in The Prostate
- Vol. 86 (3) , 357-364
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone‐Sensitive Prostate Cancer
Background: This study evaluates the impact of early modification of upfront androgen receptor signaling inhibitors (ARSI) on outcomes among patients with metastatic hormone‐sensitive prostate cancer (mHSPC). Methods: This retrospective, multicenter cohort study included 590 patients with mHSPC who received upfront ARSI combined with androgen deprivation therapy. All had a follow‐up duration of ≥ 6 months. The impact of early modification of ARSI without progression on survival outcomes was analyzed. The inverse probability of treatment weighting (IPTW) was applied to adjust for confounding factors associated with survival outcomes, comparing patients who did and did not discontinue ARSI early. Results: Upfront abiraterone acetate, apalutamide, and enzalutamide were used in 50.8%, 28.1%, and 21.0% of patients, respectively. The rates of withdrawal of the upfront ARSI and initial dose reduction were 21.2% and 6.1%, respectively. The highest withdrawal rate (33.1%) was with apalutamide, mainly due to adverse events (89.1%). Apalutamide use (odds ratio [OR] 2.39, 95% CI: 1.50–3.80) and a low‐risk CHAARTED status (OR 1.84, 95% CI: 1.08–3.14) were identified as independent risk factors for early ARSI withdrawal. IPTW analysis revealed early ARSI withdrawal (within 6 months) significantly correlated with poor castration‐resistant prostate cancer‐free survival (CRPC‐FS) ( p = 0.004) and second progression‐free survival (PFS2) ( p = 0.035). However, it had no significant relationship with overall survival ( p = 0.280). Conclusions: Early withdrawal of initial upfront ARSI was associated with poor CRPC‐FS and PFS2 among mHSPC patients. Maximizing the effectiveness of first‐line treatment requires optimal management of ARSI therapy. Trial Registration: jRCTs021180021.
- 11 September 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (12) , 1440-1442
Can artificial intelligence pass the Japanese urology board examinations?
- 11 September 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (12) , 1440-1442
Can artificial intelligence pass the Japanese urology board examinations?
- Open Access
- 16 September 2022
- Published by Wiley in IJU Case Reports
- Vol. 6 (1) , 22-25
Abdominal compartment syndrome after endoscopic combined intrarenal surgery
Introduction: We report a case of abdominal compartment syndrome due to hydroperitoneum after endoscopic combined intrarenal surgery.Case presentation: A 56‐year‐old woman with a left staghorn calculus underwent endoscopic combined intrarenal surgery as a two‐staged procedure and developed a distended abdomen, cyanosis of both legs, and hypotension immediately after the second operation. A computed tomography scan showed hydroperitoneum. We performed urgent laparotomy and evacuated approximately 2 L of nearly transparent fluid. No peritoneal injury was detected. Postoperatively, she required intensive care for shocked liver and acute kidney injury.Conclusion: Hydroperitoneum after endoscopic combined intrarenal surgery is a rare complication and may lead to abdominal compartment syndrome or a condition where intra‐abdominal pressure exceeds 20 mmHg, causing impaired organ perfusion. Delayed drainage can be fatal.
- 16 September 2022
- Published by Wiley in IJU Case Reports
- Vol. 6 (1) , 22-25
Open AccessAbdominal compartment syndrome after endoscopic combined intrarenal surgery
Introduction: We report a case of abdominal compartment syndrome due to hydroperitoneum after endoscopic combined intrarenal surgery.Case presentation: A 56‐year‐old woman with a left staghorn calculus underwent endoscopic combined intrarenal surgery as a two‐staged procedure and developed a distended abdomen, cyanosis of both legs, and hypotension immediately after the second operation. A computed tomography scan showed hydroperitoneum. We performed urgent laparotomy and evacuated approximately 2 L of nearly transparent fluid. No peritoneal injury was detected. Postoperatively, she required intensive care for shocked liver and acute kidney injury.Conclusion: Hydroperitoneum after endoscopic combined intrarenal surgery is a rare complication and may lead to abdominal compartment syndrome or a condition where intra‐abdominal pressure exceeds 20 mmHg, causing impaired organ perfusion. Delayed drainage can be fatal.
- Open Access
- 16 September 2021
- Published by Wiley in IJU Case Reports
- Vol. 5 (1) , 19-22
Extramedullary plasmacytoma of the ureter
Introduction We report a rare case of an extramedullary plasmacytoma of the ureter. Case presentation A 77-year-old man was referred to our hospital because of left hydronephrosis. Computed tomography showed a tumor in the left ureter, and tumor invasion into the periureteric fat was suspected. Urine cytology showed Eatypical cells whose nuclei were hyperchromatic (class IIIb). The left ureteral tumor was diagnosed as urothelial carcinoma (cT3N0M0) preoperatively. Subsequently, we performed laparoscopic radical nephroureterectomy with bladder cuff excision. The tumor was pathologically diagnosed as a plasmacytoma. Postoperative positron emission tomography did not reveal abnormal uptake, and bone marrow aspiration findings were normal. Consequently, the left ureter tumor was diagnosed as an extramedullary plasmacytoma of the ureter. Conclusion Extramedullary plasmacytoma commonly occurs in the upper respiratory tract or upper gastrointestinal tract. Extramedullary plasmacytoma of the ureter is rare. This is only the fourth reported case of extramedullary plasmacytoma of the ureter.
- 16 September 2021
- Published by Wiley in IJU Case Reports
- Vol. 5 (1) , 19-22
Open AccessExtramedullary plasmacytoma of the ureter
Introduction We report a rare case of an extramedullary plasmacytoma of the ureter. Case presentation A 77-year-old man was referred to our hospital because of left hydronephrosis. Computed tomography showed a tumor in the left ureter, and tumor invasion into the periureteric fat was suspected. Urine cytology showed Eatypical cells whose nuclei were hyperchromatic (class IIIb). The left ureteral tumor was diagnosed as urothelial carcinoma (cT3N0M0) preoperatively. Subsequently, we performed laparoscopic radical nephroureterectomy with bladder cuff excision. The tumor was pathologically diagnosed as a plasmacytoma. Postoperative positron emission tomography did not reveal abnormal uptake, and bone marrow aspiration findings were normal. Consequently, the left ureter tumor was diagnosed as an extramedullary plasmacytoma of the ureter. Conclusion Extramedullary plasmacytoma commonly occurs in the upper respiratory tract or upper gastrointestinal tract. Extramedullary plasmacytoma of the ureter is rare. This is only the fourth reported case of extramedullary plasmacytoma of the ureter.